Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania.

Journal article

Nasser A. et al, (2021), Blood Adv, 5, 1403 - 1411

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.

Journal article

Eyre TA. et al, (2021), Haematologica, 106, 284 - 287

Twelve Cases of Hb Manitoba [α102(G9)Ser→Arg]: the Fluctuation in the Variant Expression.

Journal article

Khalil MSM. et al, (2020), Hemoglobin, 44, 442 - 445

Fifteen Cases of Hb J-Meerut: The Rare Association with Hb E and/or HBA1: c.-24C>G (or HBA2) Variants.

Journal article

Khalil MSM. et al, (2020), Hemoglobin, 44, 364 - 367

Comparative analysis of somatic variant calling on matched FF and FFPE WGS samples.

Journal article

de Schaetzen van Brienen L. et al, (2020), BMC Med Genomics, 13

A Wide Spectrum Study of α-Globin Chain Variants: Cases from the UK.

Journal article

Khalil MSM. et al, (2020), Hemoglobin, 1 - 6

Comparative analysis of targeted therapies in relapsed/refractory chronic lymphocytic leukemia (R/R CLL)

Conference paper

Mato A. et al, (2020), LEUKEMIA & LYMPHOMA, 61, 193 - 195

Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification

Conference paper

Ridout K. et al, (2020), LEUKEMIA & LYMPHOMA, 61, 167 - 168

Factors impacting treatment selection in treatment-naive patients with CLL: a multicenter study

Conference paper

Rhodes J. et al, (2020), LEUKEMIA & LYMPHOMA, 61, 104 - 105

Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study

Conference paper

Munir T. et al, (2020), LEUKEMIA & LYMPHOMA, 61, 227 - 228

Next-generation sequencing of TP53 mutations negates the need for FISH assessment in the investigation of TP53 aberrations

Conference paper

Catherwood MA. et al, (2020), LEUKEMIA & LYMPHOMA, 61, 197 - 198

Load More